Testing an implantable device to study drug response in prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This early-phase study uses a tiny implant placed during prostate cancer surgery planning to help researchers measure how tumors respond to treatment while still in the body. The results may help improve future treatment choices for men with intermediate- or high-risk prostate cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 22 years or older and able to understand and sign consent.
- You must be planning a radical prostatectomy (standard surgery to remove the prostate).
- Your prostate cancer must be intermediate- or high-risk (based on biopsy results and an MRI lesion).
- You must be medically stable for biopsy and surgery, and the research team must be able to place and later remove the implant safely.
- You must agree to genetic testing and sharing de-identified results with NIH databases.
- You must agree to follow sperm/sex precautions during treatment and for 28 days after the last ipatasertib dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new device that uses tiny electrical sensors to help surgeons check if all the cancer has been removed during prostate cancer surgery. It could give real-time feedback so the surgeon can remove leftover cancer right away.
This study tests technology that uses imaging scans to help doctors locate and reach abnormalities during surgical or interventional procedures. The goal is to make these image-guided procedures more accurate and safer for patients.
This study tests a new oral tablet (HRS-7525) for men with advanced prostate cancer that has spread. It aims to see if the drug is safe and effective, and may offer a new treatment option for those who have not responded to standard therapies.
This study uses a special kind of MRI to better “map” prostate cancer inside the prostate. Researchers compare the MRI results with the detailed tissue exam after prostate surgery to see how accurate the imaging is.
This trial is testing a new way to treat prostate cancer by placing a tiny radioactive seed directly into the main tumor. It's for men with early-stage, slow-growing cancer who have just one visible tumor on MRI.
This study collects and measures “biomarkers” (measurable signs in the body) from people with prostate cancer who are about to have surgery or radiation. The goal is to understand how prostate cancer behaves during treatment, which may help improve care in the future.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.